• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 30, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Low-Dose Iohexol Infusion Tracks Kidney Filtration in Pigs

by
October 30, 2026
in Health
Reading Time: 3 mins read
0
Low-Dose Iohexol Infusion Tracks Kidney Filtration in Pigs

Low-Dose Iohexol Infusion Tracks Kidney Filtration in Pigs

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have developed and validated a protocol for continuously infusing low doses of the contrast agent iohexol into anesthetized pigs, allowing glomerular filtration rate to be measured accurately and precisely over several hours.

The pig is considered a suitable animal model for studying human acute kidney injury, but precise methods for determining glomerular filtration rate are rarely applied in dynamic physiological conditions. Iohexol is already a preferred marker for precise filtration measurement in humans and has been validated in pigs. The idea behind the new approach, called continuous infusion of low dose iohexol, or CILDI, is that after an initial equilibration period, a steady infusion can be used to monitor changes in filtration rate as conditions change. Before it could be used in dynamic experiments, however, a protocol first had to be established under stable conditions.

To build that protocol, the team first studied iohexol pharmacokinetics in three anesthetized pigs and used the resulting data to tailor dosing. In the main experiment, nine anesthetized pigs of both sexes, weighing between 29.5 and 37 kilograms, were surgically instrumented and then given iohexol as a bolus dose of 1.16 milliliters followed by a continuous infusion of 0.4 milliliters per hour of Omnipaque 300 mg I/mL. Blood and urine samples were collected over eight hours, and iohexol concentrations were analyzed by LC/MS-MS. Time to plateau was estimated both by nonlinear fitting of concentration-time profiles and by visual assessment of decay curves.

The results showed that a plateau plasma concentration was achieved within 120 minutes. Plasma iohexol clearance, which served as the measured filtration rate, averaged 53.7 ± 7.5 mL/min. When the researchers compared plasma clearance with renal iohexol clearance, the direct measure of how much iohexol the kidneys actually excreted, they found no significant difference between the two, with a bias of only 2.15 mL/min. Accuracy for the method was defined in advance as a mean difference of less than 10 percent between plasma and renal clearance, a threshold the protocol met.

The comparison with creatinine was less flattering to the traditional marker. Creatinine clearance was significantly higher than plasma iohexol clearance, with a bias of 13.29 mL/min and a p-value of 0.004, indicating that creatinine overestimates filtration in this setting. Precision also favored iohexol. The mean coefficient of variation for plasma iohexol clearance was 2.3 percent, while the mean coefficient of variation for serum creatinine was 5.6 percent, a mean difference of −3.3 percent that was statistically significant.

Perhaps the most consequential finding for future experiments concerns sensitivity to change. Within individual animals, changes in mean arterial pressure were positively associated with iohexol plasma clearance, with a p-value of 0.003, but showed no significant association with creatinine, which had a p-value of 0.107.

The authors conclude that the tailored CILDI protocol achieved plateau plasma concentrations by 120 minutes in pigs with normal renal function and provided accurate and precise measurement of filtration rate thereafter.

For the research community working with pig models of kidney injury, the practical significance is straightforward. The protocol offers a way to follow filtration rate continuously in anesthetized animals with a small bolus and a modest infusion rate, using a marker already trusted in human nephrology, and with far less noise than serum creatinine.

Subject of Research: A continuous low-dose iohexol infusion protocol for measuring glomerular filtration rate in anesthetized pigs

Article Title: Continuous infusion of low dose iohexol as an accurate and precise method for determining glomerular filtration rate in pigs

Article References: Jakobsen, K., Backmann, H. J., Kildal, A. B., Fuskevåg, O.-M., Nordhus, K. C., Haug, B. H., Forsdahl, G., & Ytrebø, L. M. (2026). Continuous infusion of low dose iohexol as an accurate and precise method for determining glomerular filtration rate in pigs. BMC Nephrology. https://doi.org/10.1186/s12882-026-05452-5

Image Credits: AI Generated

DOI: 10.1186/s12882-026-05452-5

Keywords: iohexol, glomerular filtration rate, pigs, acute kidney injury, pharmacokinetics, creatinine clearance, LC-MS/MS, renal clearance, animal model, nephrology, Continuous, infusion

News Source: Jerry Hayes. (October 30, 2026). Low-Dose Iohexol Infusion Tracks Kidney Filtration in Pigs. Scienmag.

Tags: acute kidney injuryanimal modelcontinuouscreatinine clearanceglomerular filtration rateinfusioniohexolLC-MS/MSnephrologyPharmacokineticspigsrenal clearance
Share12Tweet7Share2ShareShareShare1

Related Posts

Pyrazolo[3,4-b]pyridine emerges as a privileged scaffold in anti-Alzheimer's drug design

Pyrazolo[3,4-b]pyridine emerges as a privileged scaffold in anti-Alzheimer’s drug design

October 30, 2026
Microglial Activity Patterns Track Tau Buildup in Early Alzheimer's Disease

Microglial Activity Patterns Track Tau Buildup in Early Alzheimer’s Disease

October 30, 2026

Lipid and Inflammatory Markers Show Weak, Inconsistent Links to Macular Degeneration

October 30, 2026

Declining fertility rates may reshape future hereditary angioedema case numbers

October 30, 2026

POPULAR NEWS

  • Inflammation-Weighted Nutrition Score Predicts Survival After Liver Cancer Surgery

    Inflammation-Weighted Nutrition Score Predicts Survival After Liver Cancer Surgery

    29 shares
    Share 12 Tweet 7
  • RAS Inhibitor Daraxonrasib Redefines Pancreatic Cancer Treatment After FDA Approval

    29 shares
    Share 12 Tweet 7
  • Few Ethiopian Mothers Receive Quality Care Across Maternity Continuum

    29 shares
    Share 12 Tweet 7
  • Particle Swarm Optimization Steers Client Selection in Decentralized Federated Learning

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Hybrid Deep Learning Model Detects Intrusions in Wireless Sensor Networks

Pyrazolo[3,4-b]pyridine emerges as a privileged scaffold in anti-Alzheimer’s drug design

Microglial Activity Patterns Track Tau Buildup in Early Alzheimer’s Disease

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.